The Rising Price of Eating Well: Why a Healthy Diet Costs More—Yet Remains Out of Reach for Billions
By Business Access TV News DeskJanuary 13, 2026 A healthy diet is widely promoted as one…


In a significant move for both cancer treatment and patient care, the U.S. Food and Drug Administration (FDA) has granted approval for a new injectable version of Opdivo, a widely used cancer medication developed by Bristol Myers Squibb (BMS). This new formulation is expected to revolutionize the treatment process by offering greater convenience for patients, while also providing BMS with an opportunity to maintain its revenue streams as it faces the expiration of the patent for the intravenous (IV) version in the coming years.
Understanding Opdivo and its Mechanism of Action
Opdivo is classified as a PD-1 inhibitor, part of a family of drugs that work by enhancing the body’s immune response against cancer. These drugs function by lifting the natural “brakes” that prevent the immune system from attacking cancer cells, thereby increasing the body’s ability to fight various types of cancer. Until now, Opdivo has been administered solely via intravenous infusion, a process that requires patients to spend hours in medical settings. With the approval of the injectable version, known as Opdivo Qvantig, patients can now receive their treatment in a fraction of the time—just minutes compared to the hours-long IV infusions.
The Advantages of Opdivo Qvantig
Opdivo Qvantig has received FDA approval to treat most of the solid tumor conditions previously authorized for the IV formulation. The new injectable version can be used as a standalone treatment, maintenance therapy, or in combination with chemotherapy. This offers healthcare providers and patients a quicker, more convenient alternative to the traditional method, which could improve overall patient satisfaction and adherence to treatment regimens.
Starting in early January, Opdivo Qvantig will be available to patients, priced at the same level as the existing IV version. For the lower dose, the IV infusion costs approximately $7,635 every two weeks, while the higher 480-milligram dose is priced at $15,269 and administered every four weeks. The new injectable option aims to maintain similar pricing to the current infusion treatments, making it a competitive offering within the oncology market.
Clinical Trial Success and FDA Approval
The FDA’s approval of Opdivo Qvantig was bolstered by positive data from a late-stage clinical trial that showed the injectable formulation was not inferior to the IV version for treating patients with advanced kidney cancer who had already received prior systemic therapy. This successful trial, combined with the approval of the injectable version, marks a major milestone in cancer treatment innovation. Opdivo Qvantig was developed in collaboration with Halozyme Therapeutics, which contributed its cutting-edge drug delivery technology to enable a faster and more convenient treatment experience for patients.
Bristol Myers Squibb’s Strategic Shift
With patents for several of its older drugs, including the widely-used cancer treatment Revlimid and the blood thinner Eliquis, nearing expiration, BMS has been focusing more on expanding its portfolio with new and innovative treatments. Opdivo Qvantig represents a key part of this strategy, providing the company with a potentially lucrative product that meets the growing demand for more convenient cancer therapies.
As BMS continues to navigate the challenges posed by patent expirations, the approval of Opdivo Qvantig offers an opportunity for growth through the development of newer, more patient-friendly formulations. The approval of the injectable version highlights the company’s commitment to improving patient outcomes and expanding its product offerings in the oncology market.
Looking Ahead
As the healthcare landscape continues to evolve, innovations like Opdivo Qvantig will be at the forefront of improving cancer care. For patients, the switch from lengthy IV infusions to quick injections could transform their treatment experience, allowing them to receive life-saving therapy with greater ease. For BMS, this approval is a critical step in securing future growth and maintaining a strong position within the competitive oncology sector.
With the promising clinical data and the added convenience for patients, Opdivo Qvantig could become a cornerstone of cancer treatment in the coming years, and BMS is poised to capitalize on this breakthrough to sustain its leadership in the pharmaceutical industry.
For feedback: contact the BATV Editorial Division at: info@batvja.com

This Post Has 0 Comments